Bottom line
SHSAX vs XLV: the short answer
SHSAX (Blackrock Health Sciences Opportunities Portfolio) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
But SHSAX is far broader, holding 155 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 1.11% — a difference of $103 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +4.5% for SHSAX.
SHSAX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
SHSAX vs XLV side by side
| SHSAX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | BlackRock | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.11% | 0.08% |
| Annual cost per $10k | $111 | $8 |
| 10-yr cost on $10k (prospectus) | $1,806 | $103 |
| Max front load | 5.25% | None |
| 12b-1 fee | 0.25% | 0.02% |
| 1-yr return | +9.9% | +14.5% |
| 5-yr return (annualized) | +4.5% | +8.1% |
| 10-yr return (annualized) | +9.0% | +9.8% |
| Best quarter | +17.5% | +14.5% |
| Worst quarter | −11.5% | −12.7% |
| Net assets (fund) | $5.9B | $40.6B |
| Number of holdings | 155 | 65 |
| Portfolio turnover | 49% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHSAX | XLV | Difference |
|---|---|---|---|
| 2025 | +16.0% | +14.5% | +1.5% |
| 2024 | +3.9% | +2.5% | +1.4% |
| 2023 | +3.6% | +2.0% | +1.6% |
| 2022 | −5.9% | −2.1% | −3.9% |
| 2021 | +11.8% | +25.9% | −14.1% |
| 2020 | +19.5% | +13.3% | +6.2% |
| 2019 | +25.3% | +20.7% | +4.6% |
| 2018 | +8.0% | +6.3% | +1.7% |
| 2017 | +24.8% | +21.7% | +3.1% |
| 2016 | −6.1% | −2.8% | −3.2% |
Source: Fund prospectus bar charts
Holdings overlap
17 of SHSAX's top 25 holdings also appear in XLV's top 25.
| Holding | SHSAX | XLV |
|---|---|---|
| Eli Lilly & Company | 12.29% | 16.51% |
| Johnson & Johnson | 8.77% | 10.64% |
| Unitedhealth Group Inc | 6.10% | 6.57% |
| Merck & Company Inc | 4.94% | 5.52% |
| Gilead Sciences Inc | 4.19% | 2.73% |
| Abbvie Inc | 3.94% | 7.74% |
| Amgen Inc | 3.37% | 3.40% |
| Thermo Fisher Scientific Inc | 3.02% | 3.24% |
| Vertex Pharmaceuticals Inc | 2.74% | 2.19% |
| Pfizer Inc | 2.61% | 2.39% |
| Danaher Corp | 2.00% | 2.09% |
| Abbott Laboratories | 1.97% | 2.75% |
| Intuitive Surgical Inc | 1.95% | 2.45% |
| Boston Scientific Corp | 1.59% | 1.10% |
| Elevance Health Inc | 1.56% | 1.46% |
Source: SEC Form N-PORT
SHSAX top 10
- Eli Lilly & Company — 12.29%
- Johnson & Johnson — 8.77%
- Unitedhealth Group Inc — 6.10%
- Merck & Company Inc — 4.94%
- Gilead Sciences Inc — 4.19%
- Abbvie Inc — 3.94%
- Amgen Inc — 3.37%
- Thermo Fisher Scientific Inc — 3.02%
- Vertex Pharmaceuticals Inc — 2.74%
- Pfizer Inc — 2.61%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between SHSAX and XLV?
Which is cheaper, SHSAX or XLV?
Should I own both SHSAX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.